Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)
Information source: Schering-Plough
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Mycoses
Intervention: Posaconazole or alternative fungal treatment (Drug)
Phase: N/A
Status: Not yet recruiting
Sponsored by: Schering-Plough
Summary
The purpose of this program is to determine the frequency of the use of Posaconazole in
immunocompromised patients refractory to first line therapy receiving therapeutic treatment
based on different pathogens in comparison to other antifungal therapy.
A further objective is to determine the frequency of the use of Posaconazole in
immunocompromised patients receiving prophylactic treatment in comparison to other antifungal
prophylaxis.
Clinical Details
Official title: P05532 Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections (IFIs) in Immuncompromised Patients in Austria. Version 1, 08-Nov-2007.
Study design: Cohort, Prospective
Primary outcome: Safety: adverse events
Secondary outcome: Baseline: Patient demographic data; Disease history; Underlying diseases; Diagnosis; Previous therapies; Environmental risk factors; Host factors
Performance statusTreatment and follow up period: Performance status; Medication; Duration of treatment; Frequency of infectious episodes; Management of infections Adverse events; Survival status
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Immunocompromised patients with refractory IFI
- Patients eligible for prophylactic treatment due to anticipated neutropenia for more
than 7 days.
Exclusion Criteria:
- None
Locations and Contacts
Additional Information
Starting date: August 2008
Ending date: June 2011
Last updated: August 12, 2008
|
